Advertisement
CLPT vs ISRG
Which Stock Would AI Choose? ClearPoint Neuro (CLPT) vs. Intuitive Surgical (ISRG) Stock Comparison
Key Takeaways
- CLPT (ClearPoint Neuro) is a small-cap medical device and drug-delivery company focused on brain and spine navigation; ISRG (Intuitive Surgical) is a large-cap leader in robotic-assisted surgery.
- CLPT delivered roughly 20% comparable sales growth in the fourth quarter of 2025, with full-year revenue near $37 million.
- ISRG grew full-year 2025 revenue about 21% to roughly $10.06 billion, driven by procedure volume and da Vinci 5 placements.
- The two companies differ sharply on profitability: ISRG is highly profitable, while CLPT remains unprofitable as it scales.
- Risk profiles diverge, with CLPT carrying execution and funding risk and ISRG facing valuation and competitive pressure.
Introduction
Investors evaluating medical technology often weigh established scale against earlier-stage growth potential. This stock comparison examines CLPT, a developing player in neurosurgical navigation and cell-and-gene therapy delivery, against ISRG, a global pioneer in robotic-assisted surgery. The two companies operate in adjacent areas of healthcare technology yet represent very different profiles in terms of size, maturity, and profitability. Traders focused on relative performance and market positioning may find this contrast useful, as it highlights the trade-offs between a high-margin industry leader and a smaller, faster-growing company pursuing a specialized opportunity in the central nervous system.
CLPT Overview and Recent Performance
CLPT, or ClearPoint Neuro, develops devices, software, and services that enable precise navigation to the brain and spine, including its flagship ClearPoint Neuro Navigation System. The company also partners with biotech firms to support direct delivery of therapeutics to the central nervous system in preclinical studies and clinical trials. In recent quarters, CLPT has shown accelerating revenue growth, reporting about 20% comparable sales growth in the fourth quarter of 2025 and full-year 2025 revenue of roughly $37 million, up from $31.4 million in 2024. The company completed its acquisition of IRRAS Holdings in November 2025, adding the IRRAflow product line to its neurosurgery portfolio. Management guided to 2026 revenue between $54 million and $60 million. Despite this momentum, CLPT remains unprofitable, posting a 2025 net loss of about $25.5 million, and holds cash of approximately $45.9 million as it invests in infrastructure ahead of anticipated commercialization of neuro cell-and-gene therapies.
ISRG Overview and Recent Performance
ISRG, or Intuitive Surgical, is a global leader in minimally invasive care and the pioneer of robotic-assisted surgery, best known for its da Vinci surgical systems and the Ion endoluminal system. The company's recent market activity has been defined by strong procedure growth and a large-scale product cycle around its newest da Vinci 5 platform. Full-year 2025 revenue grew approximately 21% to about $10.06 billion, with roughly 3.15 million da Vinci procedures performed, up about 18% year over year. Fourth-quarter revenue of about $2.87 billion reflected higher system placements and recurring instrument and accessory sales. For 2026, ISRG guided da Vinci procedure growth of 13% to 15%, a deceleration from 2025. The company's scale, installed base of more than 11,000 da Vinci systems, and recurring revenue model support strong profitability, though its premium valuation and rising competition in surgical robotics have shaped recent sentiment.
Trending AI Robots
For traders seeking a systematic view of stocks like CLPT and ISRG, Tickeron's Trending AI Robots page offers a curated selection of AI trading bots. Tickeron hosts hundreds of AI Trading Bots that trade thousands of different tickers, each with distinct trading styles, strategies, timeframes, performance statistics, and sets of securities they monitor. Rather than listing every available bot, the Trending AI Robots section highlights only the bots considered most suitable for current market conditions. Explore the page to see which automated strategies are currently gaining traction and how their approaches might apply to names across the healthcare technology sector.
Head-to-Head Comparison
The clearest contrast between these two stocks is scale and stage. ISRG generates roughly $10 billion in annual revenue with strong operating margins and a diversified, recurring income stream, whereas CLPT produces about $37 million in annual revenue and is still funding its path to profitability. In growth drivers, ISRG relies on procedure volume, system placements, and upgrades such as the da Vinci 5, while CLPT depends on disposables, neurosurgery adoption, and the long-term commercialization of gene-and-cell therapies by its biotech partners. Risk profiles also differ: CLPT carries execution, integration, and financing risk as a small-cap, whereas ISRG faces a high valuation, a decelerating procedure-growth outlook, and intensifying competition. Sector exposure is related but not identical, with ISRG concentrated in surgical robotics and CLPT in neuro-navigation and drug delivery.
Tickeron AI Verdict
Based on observable trend consistency, stability, catalysts, and relative positioning, Tickeron's AI would likely favor ISRG in the current environment. The company's established profitability, recurring revenue base, large installed system footprint, and consistent procedure growth provide a more stable and verifiable trend than CLPT's earlier-stage, unprofitable profile. That said, CLPT presents a higher-growth, higher-risk opportunity tied to emerging cell-and-gene therapy adoption, which may appeal to more speculative strategies. The AI assessment is probabilistic rather than definitive, and relative positioning could shift as new catalysts, earnings reports, or shifts in sector sentiment emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLPT is a Hold and ISRG is a StrongBuy.
CLPT sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for CLPT moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CLPT as a result. In 82 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
CLPT moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CLPT entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CLPT's RSI Indicator exited the oversold zone, 26 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 69 cases where CLPT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for CLPT just turned positive on October 26, 2026. Looking at past instances where CLPT's MACD turned positive, the stock continued to rise in 41 of 54 cases over the following month. The odds of a continued upward trend are 76%.
Following a +4.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLPT advanced for three days, in 216 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
CLPT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CLPT's P/B Ratio (29.893) is slightly higher than the industry average of (3.837). P/E Ratio (-8.949) is within average values for comparable stocks, (2.078). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (9.268) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. CLPT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Aroon Indicator for ISRG shows an upward move is likely
ISRG's Aroon Indicator triggered a bullish signal on October 23, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 264 similar instances where the Aroon Indicator showed a similar pattern. In 187 of the 264 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on ISRG as a result. In 54 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
Following a +5.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where ISRG advanced for three days, in 210 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
Bearish Trend Analysis
The 10-day RSI Indicator for ISRG moved out of overbought territory on October 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 10 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 27%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 14 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ISRG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
ISRG broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. ISRG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 51 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ISRG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 78 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.637) is normal, around the industry mean (4.942). P/E Ratio (50.247) is within average values for comparable stocks, (37.224). Projected Growth (PEG Ratio) (1.931) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.876).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
CLPT | ISRG | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 64 | 84 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 31 Undervalued | 80 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 72 | |
SMR RATING 1..100 | 100 | 51 | |
PRICE GROWTH RATING 1..100 | 87 | 43 | |
P/E GROWTH RATING 1..100 | 13 | 78 | |
SEASONALITY SCORE 1..100 | 90 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CLPT's Valuation (31) in the null industry is somewhat better than the same rating for ISRG (80) in the Medical Specialties industry. This means that CLPT’s stock grew somewhat faster than ISRG’s over the last 12 months.
ISRG's Profit vs Risk Rating (72) in the Medical Specialties industry is in the same range as CLPT (100) in the null industry. This means that ISRG’s stock grew similarly to CLPT’s over the last 12 months.
ISRG's SMR Rating (51) in the Medical Specialties industry is somewhat better than the same rating for CLPT (100) in the null industry. This means that ISRG’s stock grew somewhat faster than CLPT’s over the last 12 months.
ISRG's Price Growth Rating (43) in the Medical Specialties industry is somewhat better than the same rating for CLPT (87) in the null industry. This means that ISRG’s stock grew somewhat faster than CLPT’s over the last 12 months.
CLPT's P/E Growth Rating (13) in the null industry is somewhat better than the same rating for ISRG (78) in the Medical Specialties industry. This means that CLPT’s stock grew somewhat faster than ISRG’s over the last 12 months.
| CLPT | ISRG | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 76% | 2 days ago 27% |
| Stochastic ODDS (%) | 2 days ago 77% | 2 days ago 57% |
| Momentum ODDS (%) | 2 days ago 85% | 2 days ago 68% |
| MACD ODDS (%) | 2 days ago 76% | N/A |
| TrendWeek ODDS (%) | 2 days ago 77% | 2 days ago 64% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 66% |
| Advances ODDS (%) | 9 days ago 80% | 6 days ago 66% |
| Declines ODDS (%) | 3 days ago 87% | 2 days ago 61% |
| BollingerBands ODDS (%) | 2 days ago 75% | 2 days ago 47% |
| Aroon ODDS (%) | 2 days ago 85% | 2 days ago 71% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CLPT’s FA Score shows that 2 FA rating(s) are green while ISRG’s FA Score has 0 green FA rating(s).
- CLPT’s FA Score: 2 green, 3 red.
- ISRG’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CLPT’s TA Score shows that 6 TA indicator(s) are bullish while ISRG’s TA Score has 3 bullish TA indicator(s).
- CLPT’s TA Score: 6 bullish, 4 bearish.
- ISRG’s TA Score: 3 bullish, 4 bearish.
Price Growth
CLPT (@Medical/Nursing Services) experienced а +14.16% price change this week, while ISRG (@Pharmaceuticals: Other) price change was +3.75% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +2.09%. For the same industry, the average monthly price growth was -5.46%, and the average quarterly price growth was -6.19%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.23%. For the same industry, the average monthly price growth was -3.03%, and the average quarterly price growth was +10.30%.
Reported Earning Dates
CLPT is expected to report earnings on Mar 03, 2027.
ISRG is expected to report earnings on Jan 26, 2027.
Industries' Descriptions
@Medical/Nursing Services (+2.09% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (+0.23% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
CLPT and
Correlation & Price change
A.I.dvisor indicates that over the last year, CLPT has been loosely correlated with ICUI. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if CLPT jumps, then ICUI could also see price increases.
| Ticker / NAME | Correlation To CLPT | 1D Price Change % | ||
|---|---|---|---|---|
| CLPT | 100% | +7.19% | ||
| ICUI - CLPT | 57% Loosely correlated | -1.66% | ||
| ISRG - CLPT | 46% Loosely correlated | -1.27% | ||
| A - CLPT | 45% Loosely correlated | +0.87% | ||
| NVST - CLPT | 45% Loosely correlated | -0.34% | ||
| SMTI - CLPT | 43% Loosely correlated | -0.55% | ||
More | ||||